Sobre el grupo
Investigador Principal
José Miguel Arbonés Mainar
Equipo
Alejandro Sanz París, Ana Belén Julián Gomara, Ana Palomares Cano, Carmen Yagüe Caballero, Cristina Polo Cuadro, Diego Casas Deza, Mª Pilar García Sobreviela, Miguel Angel Dobón Rascón, Raquel Del Moral Bergos, Silvia Espina Cadena, Silvia Lorente Cebrián, Vanesa Bernal Monterde
Instituto Aragonés de Ciencias de la Salud
ADIPOFAT es un grupo multidisciplinar reconocido como grupo de referencia por el Gobierno de Aragón. Estudiamos los fenómenos metabólicos asociados a la obesidad con especial interés en los trastornos hepáticos. También las consecuencias de la desnutrición que ocurre en distintas patologías y las interacciones entre la dieta y los genes (Nutrición personalizada). Desde su nacimiento se han incorporado al grupo investigadores básicos y clínicos de distintas especialidades con el fin de producir una investigación traslacional de excelencia.
Líneas de Investigación
Efectos de la apolipoproteína E en la diabetes y el sindrome metabolico
Expandibilidad del tejido adiposo. Biomarcadores para determinar el límite de expansión y las complicaciones de la obesidad
Publicaciones más relevantes
2019
McCulloh DH, Alikani M, Norian J, Kolb B, Arbones JM, Munné S. Controlled ovarian hyperstimulation (COH) parameters associated with euploidy rates in donor oocytes. Eur J Med Genet. 2019 Jun 25:103707. doi: 10.1016/j.ejmg.2019.103707. [Epub ahead of print]
Matia Martin P, Robles Agudo F, Lopez Medina JA, Sanz Paris A, Tarazona Santabalbina F, Domenech Pascual JR, Lopez Penabad L, Sanz Barriuso R; GluceNut Study Group. Effectiveness of an oral diabetes-specific supplement on nutritional status, metabolic control, quality or life, and functional status in elderly patients. A multicentre study. Clin Nutr. 2019 Jun;38(3):1253-1261.
Gil-Iturbe E, Arbones-Mainar JM, Moreno-Aliaga MJ, Lostao MP. GLUT12 and adipose tissue: Expression, regulation and its relation with obesity in mice. Acta Physiol 2019 Apr 19
Leroux M, Lemery T, Boulet N, Briot A, Zakaroff A, Bouloumié A, Andrade F, Pérez-Matute P, Arbones-Mainar JM, Carpéné C. Effects of the amino acid derivatives, β-hydroxy-β-methylbutyrate, taurine, and N-methyltyramine, on triacylglycerol breakdown in fat cells. J Physiol Biochem 2019 Mar 27
Úrsula M. Jariod-Ferrer, Jose M. Arbones-Mainar, Marina A. Gavin-Clavero, M. Victoria Simón- Sanz, Ignacio Moral-Saez, Ana I. Cisneros-Gimeno, Javier Martinez-Trufero. Are comorbidities associated with overall survival in patients with oral squamous cell carcinoma. Journal of Oral and Maxillofacial Surgery 2019
Beatriz Lardiés-Sanchez, Jose M. Arbones-Mainar, JavierPerez-Nogueras, Antonio Serrano-Oliver, Elena Torres-Anoro, Alejandro Sanz-Paris. Neck circumference is associated with nutritional status in elderly nursing home residents. Nutrition 2019 Jan 28;62:153-157
Carpéné C., Les F., Càsedas G., Umuhoza F., Arbones-Mainar JM & López V. Elsevier. BOOK CHAPTER: Engineering and biomedical effects of commercial juices of berries, cherries, and pomegranates with high polyphenol content. Chapter 9 In: Non-alcoholic Beverages. Woodhead Publishing, 2019, 6, 259-283. ISBN: 978-0-12-815702-2
2018
Carpéné C, Pejenaute H, Del Moral R, Boulet N, Hijona E, Andrade F, Villanueva-Millán MJ, Aguirre L, Arbones-Mainar JM. The Dietary Antioxidant Piceatannol Inhibits Adipogenesis of Human Adipose Mesenchymal Stem Cells and Limits Glucose Transport and Lipogenic Activities in Adipocytes. Int J Mol Sci. 2018 Jul 17;19(7).
Perez-Diaz S, Garcia-Sobreviela MP, Gonzalez-Irazabal Y, Garcia-Rodriguez B, Espina S, Arenaz I, Arbones-Mainar JM. PTRF acts as an adipokine contributing to adipocyte dysfunctionality and ectopic lipid deposition. J Physiol Biochem. 2018 Nov;74(4):613-622.
Sanz-Paris A, Camprubi-Robles M, Lopez-Pedrosa JM, Pereira SL, Rueda R, Ballesteros-Pomar MD, Garcia Almeida JM, Cruz-Jentoft AJ. Role of Oral
Nutritional Supplements Enriched with β-Hydroxy-β-Methylbutyrate in Maintaining Muscle Function and Improving Clinical Outcomes in Various Clinical Settings. J Nutr Health Aging. 2018;22(6):664-675.
Les F, Arbonés-Mainar JM, Valero MS, López V. Pomegranate polyphenols and urolithin A inhibit α-glucosidase, dipeptidyl peptidase-4, lipase, triglyceride accumulation and adipogenesis related genes in 3T3-L1 adipocyte-like cells. J Ethnopharmacol. 2018 Jun 28;220:67-74.
Ballesteros-Pomar MD, Martínez Llinàs D, Goates S, Sanz Barriuso R, Sanz-Paris A. Cost-Effectiveness of a Specialized Oral Nutritional Supplementation for Malnourished Older Adult Patients in Spain. Nutrients. 2018 Feb 22;10(2).
Otra Actividad
PROYECTOS ACTIVOS
LIPOPROTEIN PROFILING 4 HCV INFECTION
Hepatitis C Virus (HCV) associates with lipoproteins being secreted from the liver as highly infective lipoviro particles (LVP). These LVP markedly interfere with the host lipid metabolism, ultimately causing a wide array of extrahepatic manifestations of chronic infection such as liver steatosis and cardiovascular disease (CVD). Characterizing this impaired lipid homeostasis is hence of vital importance. Yet, previous research investigating the interaction of HCV genotypes and direct-acting antiviral (DAA) treatments on lipid metabolism leaves some aspects not yet addressed. We hypothesize that measuring the number and size of lipoprotein subclasses will provide a better tool to address HCV-mediated lipid remodeling rather than the classical measures of lipoprotein-borne cholesterol. Additionally, APOE is a structural component of HCV-LVP and plays important roles in HCV infection and virion assembly. However, previous epidemiological studies have also showed conflicting results regarding the differential role of APOE isoforms on circulating lipoproteins after DAA treatments. We hypothesize that those discrepant results may result as not-yet known interactions between APOE genotypes and HCV genotypes and their modulation by HCV treatments.
The aim of this study will be 1) to clinically and epidemiologically characterize the dyslipidemia caused by the HCV as well as the persistence of the altered lipid profile after the most common DAA treatments with the application of the DOSY method to calculate lipoprotein number and size, and 2) evaluate how polymorphisms in the APOE are associated with the HCV- and DAA- mediated lipid remodeling, accounting for HCV genotypes and different DAA treatments as confounding factors.
EXPANDIBILITY OF THE ADIPOSE TISSUE. BIOMARKERS TO DETERMINE THE LIMIT OF EXPANSION AND THE COMPLICATIONS OF OBESITY.
Obesity is a chronic disease of multifactorial origin defined as an accumulation of fat that causes health problems. The subcutaneous adipose tissue is able to expand during positive energy balance. However, expandability is limited and once surpassed there is an ectopic lipid deposition in other organs, which is the origin of the metabolic disorders associated with obesity.
OBJECTIVES: 1. Study of the biogenesis of subcutaneous adipose tissue, to determine the factors that set the limit of expansion.2. Develop noninvasive biomarkers that can be used in clinical practice to differentiate obese individuals in which the expansion limit has not yet been reached (benign obesity) of those who have exceeded the limit of expansion and require aggressive therapy.
METHODOLOGY: We included patients from the Department of Surgery who will donate a sample of subcutaneous fat (prospective study). Abdominal imaging techniques will be performed to determine the level of adipose tissue expansion, metabolomics in plasma and fat to identify metabolites produced by adipocytes in the process of expansion and transcriptomics in adipose tissue to determine changes in gene expression related with the adipogenic process. Biomarkers of interest will be tested in vitro and in a validation cohort. These biomarkers will decrease the economic and health care burden of obesity on society by allowing an early detection of pathological obese individuals.